Related Experiment Video

Updated: Dec 31, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.4K

MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer

Zhongxing Liang1,2, Amber Feng3, Hyunsuk Shim4,5

  • 1Department of Radiation Oncology, Emory University, Atlanta, GA, 30322, USA. zliang@emory.edu.

Cancer Chemotherapy and Pharmacology
|January 8, 2020
PubMed
Abstract

Insights

This study reveals that high HDAC9 levels contribute to breast cancer chemoresistance. Inhibiting HDAC9, regulated by miR-30c, can resensitize resistant cells to chemotherapy, offering a new therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Histone deacetylase (HDAC) inhibitors show promise in breast cancer treatment.
  • The specific role of HDAC9 in chemoresistance is not well understood.

Purpose of the Study:

  • Investigate the role of miR-30c-regulated HDAC9 in breast cancer chemoresistance.
  • Evaluate the potential of selective HDAC9 inhibition to sensitize resistant breast cancer cells to chemotherapy.

Main Methods:

  • Quantitative PCR to measure HDAC9 and miR-30c expression in breast cancer cells and tissues.
  • Assessing the impact of selective HDAC9 inhibition on multidrug-resistant (MDR) cells.
  • Analyzing the miR-30c/HDAC9 pathway's role in mediating chemoresistance.

Main Results:

  • HDAC9 was significantly upregulated in chemoresistant breast cancer cells, inversely correlating with miR-30c levels.
  • MiR-30c mimics and HDAC9 inhibitors reversed chemoresistance in MDR breast cancer cells.

Conclusions:

  • Selective HDAC inhibition reverses chemoresistance partly by regulating miR-30c through direct targeting of HDAC9.
  • The miR-30c/HDAC9 signaling axis presents a potential therapeutic target for chemoresistant breast cancer.
Keywords:
Breast cancerChemoresistanceHDAC inhibitorHDAC9MiR-30c

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

20.6K
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K